ERBB2 and breast cancer: For instance, higher expressions of 6-phosphogluconolactonase (6PGL) and glucose-6-phosphate dehydrogenase (G6PD) suggest that the HER2 subtype of breast cancer has a more active PPP than other subtypes [124].